Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Low Nicotine Content Cigarettes (LNCs), specifically those utilized in research at the Masonic Cancer Center, University of Minnesota, are experimental tobacco products engineered to contain very low levels of nicotine (typically 0.4 mg/g of tobacco). Unlike conventional cigarettes, which contain approximately 10-15 mg/g of nicotine, these research cigarettes are designed to be non-addictive or less reinforcing. The research led by Dr. Dorothy Hatsukami and colleagues focuses on the nicotine reduction strategy, evaluating how a federal mandate to lower nicotine levels across all combustible tobacco products would affect smoking behavior, dependence, and cessation. These studies often examine the interplay between the product's pharmacology and educational messaging regarding risk perceptions and consumer choice.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Low Nicotine Content Cigarettes-Masonic Cancer Center, University of Minnesota.